Two-year Assessment of the Efficacy and Safety of Ocrelizumab in Switching Patients from Other Disease Modifying Therapies

TERZİ M., BOZ C., DEMİR C. F., ÇİLİNGİR V., HELVACI E. M.

Journal of Multiple Sclerosis, 2023 (Hakemli Dergi)